BridgeBio Pharma, Inc. Net Debt/EBITDA

Net Debt/EBITDA of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending September 30, 2022 was -8.82 (a -30.35% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA increased by 62.57%
  • Annual Net Debt/EBITDA for 2021 was -1.53 (a -656.85% decrease from previous year)
  • Annual Net Debt/EBITDA for 2020 was 0.27 (a -83.68% decrease from previous year)
  • Annual Net Debt/EBITDA for 2019 was 1.68 (a -19.07% decrease from previous year)
Visit stockrow.com/BBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of BridgeBio Pharma, Inc.

Most recent Net Debt/EBITDAof BBIO including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -8.82 -12.66 -6.15
2021 -5.42 -5.36 -5.98 -2.67 -1.53
2020 1.02 1.94 3.01 4.32 0.27
2019 5.67 8.45 0.0 0.0 1.68
2018 0.0 0.0 2.08
2017 -1.19

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology